alexa Targeting Epigenetic Mechanism as the Novel AML Therapy | OMICS International
ISSN: 2161-0681
Journal of Clinical & Experimental Pathology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

Targeting Epigenetic Mechanism as the Novel AML Therapy

Yali Dou*

Department of Pathology University of Michigan, USA

*Corresponding Author:
Yali Dou
Department of Pathology University of Michigan, USA
Tel: 734-615-1315
Fax: 734-936-7361
E-mail: [email protected]

Received date: November 27, 2012; Accepted date: November 28, 2012; Published date: November 30, 2012

Citation: Dou Y (2012) Targeting Epigenetic Mechanism as the Novel AML Therapy. J Clin Exp Pathol 2:e116. doi:10.4172/2161-0681.1000e116

Copyright: ©2012 Dou Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical & Experimental Pathology

Acute myeloid leukemia (AML) is a subtype of leukemia that has extremely poor prognosis. AML affects both children and adults with an incidence of approximately 12,000 new patients in the U.S. each year. Current treatment methods include chemotherapy, radiation and stem cell transplant. Although considerable progress has been made in understanding the causes of AML, the drugs currently used to treat these diseases are little changed over the past 40 years and yield disappointing results.The overall five-year survival rate of AML patients is less than 20%. More effective treatments are needed.

Research in recent years shows that mutations of histone methyltransferases including mixed lineage leukemia (MLL), MLL3, enhancer of zest (EZH2) and nuclear receptor binding and SET domain containing protein 1 (NSD1) are enriched in AML [1,2], suggesting epigenetic mechanism is involved in initiation and development of leukemia. They also highlight the potential of targeting epigenetic pathways as an area for development of novel therapeutics.

Indeed, several lead compounds targeting proteins (i.e. MENIN, DOT1L and BRD4) in the MLL pathway have shown therapeutic potential in the treatment of AML that carry MLL gene rearrangement [3-5]. These compounds target recruitment of MLL fusion proteins [3] or MLL fusion protein associated transcription cofactors [4,5]. As a result, they changed leukemia cell transcriptome, which is essential for proliferation and survival of cancer cells. One advantage of these compounds is that they all target leukemia blasts, which often escape conventional therapy.

The demonstrated efficacy by targeting epigenetic pathwaybreaks new ground for the treatment of AML patients. Future studieswith these leads will likely revealnovel mechanisms for subtypes of AML as well as the potentialfor developing combination therapies for this class of aggressive diseases.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 12507
  • [From(publication date):
    November-2013 - Sep 28, 2020]
  • Breakdown by view type
  • HTML page views : 8639
  • PDF downloads : 3868
Top